J. Lipid Res.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

A more recent version of this article appeared on February 1, 2008

Papers In Press, published online ahead of print October 31, 2007
J. Lipid Res., doi:10.1194/jlr.M700261-JLR200
This Article
Right arrow Full Text (Accepted Manuscript)
Right arrow Supplemental Data
Right arrow All Versions of this Article:
M700261-JLR200v1
49/2/324    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Glaros, E. N.
Right arrow Articles by Garner, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Glaros, E. N.
Right arrow Articles by Garner, B.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Submitted on June 6, 2007
Revised on October 30, 2007
Accepted on October 31, 2007

Myriocin slows progression of established atherosclerotic lesions in apolipoprotein-E gene knockout mice

Elias N. Glaros, Woojin S. Kim, Carmel M. Quinn, Wendy Jessup, Kerry-Anne Rye, and Brett Garner

Cellular Lipidology Group, Prince of Wales Medical Research Institute, Sydney, NSW 2031

Corresponding Author: brett.garner{at}unsw.edu.au

The serine palmitoyl transferase inhibitor myriocin potently suppresses the development of atherosclerosis in apoE gene knockout (apoE-/-) mice fed a high fat diet. This is associated with reduced plasma sphingomyelin and glycosphingolipid levels. Furthermore, oral administration of myriocin lowers plasma cholesterol and triglyceride levels. Here we aimed to determine if myriocin could inhibit the progression (or stimulate regression) of established atherosclerotic lesions and examine potential changes in hepatic and plasma lipid concentrations. Adult apoE-/- mice were fed a high fat diet for 30 days and lesion formation was histologically confirmed. Replicate groups of mice were then transferred to either regular chow or chow containing myriocin (dose 0.3 mg/kg/day) and maintained for a further 60 days. Myriocin significantly inhibited the progression of established atherosclerosis when combined lesion areas (aortic sinus, arch and coeliac branch point) were measured. While inhibition of lesion progression was mainly observed in the distal regions of the aorta, regression of lesion size was not detected. The inhibition of lesion progression was associated with reductions in hepatic and plasma sphingomyelin, cholesterol and triglyceride levels and increased hepatic and plasma apoA-I levels indicating that modulation of pathways associated with several classes of atherogenic lipid may be involved.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J. Lipid Res.Home page
E. N. Glaros, W. S. Kim, K.-A. Rye, J. A. Shayman, and B. Garner
Reduction of plasma glycosphingolipid levels has no impact on atherosclerosis in apolipoprotein E-null mice
J. Lipid Res., August 1, 2008; 49(8): 1677 - 1681.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
S. T. Pruett, A. Bushnev, K. Hagedorn, M. Adiga, C. A. Haynes, M. C. Sullards, D. C. Liotta, and A. H. Merrill Jr.
Thematic Review Series: Sphingolipids. Biodiversity of sphingoid bases ("sphingosines") and related amino alcohols
J. Lipid Res., August 1, 2008; 49(8): 1621 - 1639.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 All ASBMB Journals   Journal of Biological Chemistry 
 Molecular and Cellular Proteomics   ASBMB Today 
Copyright © 2007 by the American Society for Biochemistry and Molecular Biology.